Dr. Conrad Savoy has been Chief Executive Officer and President of BioPartners GmbH since May 2009. Dr. Savoy serves as the Chief Executive Officer of Obexia AG. Dr. Savoy served as Chief Scientific Officer of BioPartners GmbH since May 2007. He served as the Head of Pharma Development (hGH) of BioPartners GmbH since 2001. Dr. Savoy has a wealth of experience in the global development of pharmaceutical products, which he gained during the many years he spent with Hoffmann-La Roche prior to joining BioPartners. During his time with Roche, he served as its Global Regulatory Affairs Manager in which he was responsible for the development and implementation of the regulatory strategies for numerous novel chemical entities at various stages of clinical and technical development. Dr. Savoy has substantial experience of global regulatory authorities including the FDA and EMEA and has managed several projects reliant on the centralized European approval procedure. He has also led drug development teams responsible for CPMP hearings as well as FDA Advisory Board meetings.

Business Administration